Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Interventional × Acceptance and Commitment Therapy × Clear all

Phase

Phase NA 20 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cancer Recurrence 1

Interventions

Cyclophosphamide 558 pembrolizumab 433 Paclitaxel 397 Gemcitabine 382 Cisplatin 379 Carboplatin 374 Radiotherapy 336 fludarabine 318 Nivolumab 298 Bevacizumab 245 Docetaxel 241 Irinotecan 218 Magnetic Resonance Spectroscopy 213 Dexamethasone 200 Fluorouracil 198 Specimen Handling 194 Capecitabine 191 Rituximab 181 Cytarabine 181 fludarabine phosphate 174 Oxaliplatin 174 Biopsy 171 Temozolomide 170 Ipilimumab 166 Lenalidomide 162 Etoposide 161 Doxorubicin 152 Cetuximab 151 Leucovorin 149 Bortezomib 147

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01354041 2014-01-27

WiLLoW

University of California, San Francisco

Phase 1 Completed

Cancer Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡